Novartis is cueing up a new indication in the US for its oral therapy for complement-mediated diseases – Fabhalta – after reporting new data with the drug in ultra-rare kidney disease C3 ...

Novartis has a third FDA-approved indication for its oral therapy for complement-mediated diseases – Fabhalta – after getting a green light in ultra-rare kidney disease C3 glomerulopathy (C3G).

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

And Sanofi has a path to adequate returns. Future of Healthcategory· June 2, 2025 Novartis' Pluvicto shown to slow prostate cancer in earlier setting Novartis said on Monday that its targeted ...